Salvage Treatment for Persistent Methicillin‐ResistantStaphylococcus aureusBacteremia: Efficacy of Linezolid With or Without Carbapenem

Hee‐Chang Jang, Sung‐Han Kim, Kye Hyoung Kim, Choong Jong Kim, Shinwon Lee, Kyoung‐Ho Song, Jae Hyun Jeon, Wan Beom Park, Hong Bin Kim, Sang‐Won Park, Nam Joong Kim, Eui‐Chong Kim (+2 others)
2009 Clinical Infectious Diseases  
Background. Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high mortality rates, but no treatment strategy has yet been established. We performed this study to evaluate the efficacy of linezolid with or without carbapenem in salvage treatment for persistent MRSA bacteremia. Methods. All adult patients with persistent MRSA bacteremia for у7 days from January 2006 through March 2008 who were treated at Seoul National University Hospital were studied.
more » ... tal were studied. The results of linezolid salvage therapy with or without carbapenem were compared with those of salvage therapy with vancomycin plus aminoglycosides or rifampicin. Results. Thirty-five patients with persistent MRSA bacteremia were studied. The early microbiological response (ie, negative results for follow-up blood culture within 72 hours) was significantly higher in the linezolid-based salvage therapy group than the comparison group (75% vs 17%; ). Adding aminoglycosides or rifampicin P p .006 to vancomycin was not successful in treating any of the patients, whereas linezolid-based therapy gave an 88% salvage success rate ( ). The S. aureus-related mortality rate was lower for patients treated with a linezolid P ! .001 salvage regimen than for patients continually treated with a vancomycin-based regimen (13% vs 53%; ). P p .030 Conclusions. Linezolid-based salvage therapy effectively eradicated S. aureus from the blood for patients with persistent MRSA bacteremia. The salvage success rate was higher for linezolid therapy than for vancomycin-based combination therapy. Staphylococcus aureus is a major cause of communityacquired and nosocomial infections [1] . The organism is the second most common cause of nosocomial bacteremia in the United States [2] . Glycopeptides have been used as the main treatment for serious methicillinresistant S. aureus (MRSA) infections, including bacteremia. However, treatment failure in MRSA infections
doi:10.1086/600295 pmid:19569970 fatcat:6xhq2macrbbvfiemlxagfjt52m